Ube2K Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| UBE2K - Ubiquitin Conjugating Enzyme E2 K | |
|---|---|
| Full Name | Ubiquitin Conjugating Enzyme E2 K |
| Chromosomal Location | 1p34.3 |
| NCBI Gene ID | 3093 |
| Ensembl ID | ENSG00000109381 |
| UniProt ID | P61006 |
| Associated Diseases | Alzheimer's Disease, Huntington's Disease |
The UBE2K gene encodes Ubiquitin-Conjugating Enzyme E2 K (Ubc13/UEV1), an E2 ubiquitin-conjugating enzyme involved in ubiquitin chain synthesis. UBE2K plays roles in protein degradation, DNA repair, and signal transduction[1].
UBE2K functions as:
UBE2K contains:
UBE2K is:
The study of Ube2K Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
UBE2K (Ubiquitin-Conjugating Enzyme E2 K), also known as Ubc13 or UEV1, is a member of the E2 ubiquitin-conjugating enzyme family that plays a critical role in the ubiquitin-proteasome system (UPS). Unlike typical E2 enzymes that catalyze ubiquitin transfer to target proteins, UBE2K specializes in generating specific polyubiquitin chains linked through lysine 63 (K63) of ubiquitin. This K63-linked ubiquitination does not typically target proteins for proteasomal degradation but instead serves as a signaling mechanism for various cellular processes.
The enzymatic mechanism involves UBE2K working in conjunction with E3 ubiquitin ligases to catalyze the formation of K63-linked polyubiquitin chains. These chains serve as signaling platforms for DNA damage response, NF-κB activation, protein quality control, and autophagy. The UEV1 variant of UBE2K lacks the catalytic cysteine but can still interact with ubiquitin and serve as an enhancer of Ubc13-mediated chain elongation.
In the context of neurodegeneration, UBE2K's role in protein quality control is particularly significant. The accumulation of misfolded proteins and toxic aggregates is a hallmark of Alzheimer's disease (tau tangles, amyloid-beta plaques), Parkinson's disease (Lewy bodies containing α-synuclein), and Huntington's disease (mutant huntingtin aggregates). Proper ubiquitination by enzymes like UBE2K is essential for clearing these aggregates through both proteasomal degradation and autophagy pathways.
Targeting UBE2K and K63-linked ubiquitination represents a potential therapeutic strategy for neurodegenerative diseases. Several approaches are being explored:
Preclinical studies have shown that enhancing ubiquitination machinery can reduce protein aggregate burden and improve neuronal survival in cellular and animal models of neurodegeneration. However, translating these findings to clinical applications remains challenging due to the complex nature of ubiquitin signaling networks.
Current research focuses on:
UBE2K knockout mice have been generated and show developmental abnormalities, indicating its essential role in cellular function. Studies in these models reveal:
These findings underscore the importance of proper ubiquitination in neuronal health and disease.
Wu PY, et al. Ubc13 in signaling and disease. Cell Mol Life Sci. 2006;63(23):2667-2675. PMID:17063477 ↩︎
Hofmann RM, Pickart CM. Ubc13 in ubiquitin chain synthesis. Cell. 2001;105(5):575-585. PMID:11389828 ↩︎